Depakote
NDC Package 0074-6212-13

11-digit billing NDC: 00074621213 · Billing unit: EA · 100 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Depakote is contraindicated in patients:• with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. Marketed by Abbvie Inc., this product is identified by NDC 0074-6212 and is authorized under FDA application NDA018723.

Identification & Billing

NDC Package Code
0074-6212-13
Package Description
100 TABLET, DELAYED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
00074621213
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Depakote
Dosage Form
-
Usage Information
Depakote is contraindicated in patients:• with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. • known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)]. • with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions (5.12, 5.13, 5.14)]. • with known urea cycle disorders [see Warnings and Precautions (5.6)]. • being treated for prophylaxis of migraine headaches who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)].

Regulatory & Marketing

Labeler Name
Abbvie Inc.
FDA Application #
NDA018723
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-10-1983
End Marketing Date
10-05-2022
Listing Expiration
10-05-2022
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-6212-13 identifies a specific commercial package of 100 tablet, delayed release in 1 bottle of Depakote, labeled by Abbvie Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Abbvie Inc. on March 10, 1983. The current certification is valid through October 05, 2022.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074621213. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-6212-13
11-Digit CMS (5-4-2)
00074-6212-13

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.